Empowered Patient

Optimizing Health System Resources for Patients Needing Acute Care with Niloy Sanyal LeanTaaS
Empowered Patient

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  • Creating a Framework for Interoperability of Healthcare Information with Dave Lareau Medicomp Systems TRANSCRIPT
    on May 25, 2022 by Karen Jagoda

    Dave Lareau is the CEO of Medicomp Systems, which has spent 44 years working with providers to understand better the kinds of information that is most relevant to a diagnosis and therapeutic approach.  With 400,000 concepts and tens of millions of relevancy links and mappings to data, Medicomp is prepared to handle the flood of information expected with the standardization of person-centered care. Just finalized in January, TEFCA, the Trusted Exchange Framework, and Common Agreement is expected to provide an infrastructure for sharing information. Dave explains, "So there's a new era starting in healthcare, which is the data belongs to the patient. It doesn't belong to the provider or the organization. And now there's a framework in place for sharing it, a trusted framework. It's right in the name, TEFCA. And I think it's going to open up new possibilities, new opportunities, new challenges. And for the first time, the patient will be able to participate in the viewing and managing of their own care. It will radically change the way that people interact with information all along the continuum of care." @MedicompSys #TEFCA #ElectronicHealthRecords #EHR #DataExchange #Interoperability Medicomp.com Listen to the podcast here

  • Creating a Framework for Interoperability of Healthcare Information with Dave Lareau Medicomp Systems
    on May 25, 2022 by Karen Jagoda

    Dave Lareau is the CEO of Medicomp Systems, which has spent 44 years working with providers to understand better the kinds of information that is most relevant to a diagnosis and therapeutic approach.  With 400,000 concepts and tens of millions of relevancy links and mappings to data, Medicomp is prepared to handle the flood of information expected with the standardization of person-centered care. Just finalized in January, TEFCA, the Trusted Exchange Framework, and Common Agreement is expected to provide an infrastructure for sharing information. Dave explains, "So there's a new era starting in healthcare, which is the data belongs to the patient. It doesn't belong to the provider or the organization. And now there's a framework in place for sharing it, a trusted framework. It's right in the name, TEFCA. And I think it's going to open up new possibilities, new opportunities, new challenges. And for the first time, the patient will be able to participate in the viewing and managing of their own care. It will radically change the way that people interact with information all along the continuum of care." @MedicompSys #TEFCA #ElectronicHealthRecords #EHR #DataExchange #Interoperability Medicomp.com Download the transcript

  • Using Blockchain-Integrated Platform to Track and Manage Biospecimens with Wei Escala Eggschain TRANSCRIPT
    on May 24, 2022 by Karen Jagoda

    Wei Escala is the founder and CEO of Eggschain, the first biotech on the Bitcoin blockchain. This blockchain-integrated approach brings order to the management of tracking patient  and biospecimen information. Their goal is to bring the healthcare industry to Web3 through decentralization. Wei explains, "We're the first blockchain-enabled and blockchain-integrated inventory management and chain-of-custody solution for tracking all biospecimens. When I say all biospecimens, I mean sperm, eggs, embryos, genome, stem cells, tissues, organs, DNA and RNA, and more. So, essentially, we are the bridge between biology and blockchain. And our goal is to bring the healthcare industry to Web3 through decentralization." "Yes, a blockchain-integrated platform helps tackle the problem of centralized records. Let me talk about what might be some of the issues of centralized records. Centralized records can be lost or can become inaccessible in times of need. And we all have heard that centralized records can be corrupted and can also be hacked. So, a blockchain approach, through decentralization, brings an added layer of security or backup to the current system." @Eggschain #Eggschain #Blockchain #DigitalHealth #HealthRecords #Web3 Eggschain.com Listen to the podcast here

  • Using Blockchain-Integrated Platform to Track and Manage Biospecimens with Wei Escala Eggschain
    on May 24, 2022 by Karen Jagoda

    Wei Escala is the founder and CEO of Eggschain, the first biotech on the Bitcoin blockchain. This blockchain-integrated approach brings order to the management of tracking patient  and biospecimen information. Their goal is to bring the healthcare industry to Web3 through decentralization. Wei explains, "We're the first blockchain-enabled and blockchain-integrated inventory management and chain-of-custody solution for tracking all biospecimens. When I say all biospecimens, I mean sperm, eggs, embryos, genome, stem cells, tissues, organs, DNA and RNA, and more. So, essentially, we are the bridge between biology and blockchain. And our goal is to bring the healthcare industry to Web3 through decentralization." "Yes, a blockchain-integrated platform helps tackle the problem of centralized records. Let me talk about what might be some of the issues of centralized records. Centralized records can be lost or can become inaccessible in times of need. And we all have heard that centralized records can be corrupted and can also be hacked. So, a blockchain approach, through decentralization, brings an added layer of security or backup to the current system." @Eggschain #Eggschain #Blockchain #DigitalHealth #HealthRecords #Web3 Eggschain.com Download the transcript here

  • Developing Serotonin-3 Receptor Blocker to Treat Alcohol Use Disorder with Bill Stilley Adial Pharmaceuticals TRANSCRIPT
    on May 23, 2022 by Karen Jagoda

    Bill Stilley is the CEO and President of Adial Pharmaceuticals, which is focused on developing medicinal therapies for the treatment and prevention of addiction.  Their first drug is a genetically targeted drug to treat alcohol use disorder, otherwise known as alcoholism. Bill explains, "Yes, in the end, a lot of diseases are based on our genetics, and addiction seems to have some genetic components. I mean, for decades, it's been known that people that have had family members with an alcohol use problem have a much higher rate, and the numbers thrown around a lot are a nine times greater likelihood to have the problem themselves. Of course, some of that's going to be due to an environment, but it's clear that there's a genetic component." "So, we believe that we have identified some defects in the serotonin system of certain patients which will allow them to respond to treatment with our drug, which is a serotonin-3 receptor blocker. By that, I mean what it seems to indicate in clinical trials to date, is that we can reduce the craving that these patients have that's driven through their serotonin system to encourage them where they have a need to drink, rather than just a desire to drink." "In our phase 2 study, which is a 283 patient clinical trial that was run with our drug, patients that were on the drug that had the right genetics reduced the frequency of their drinking by almost 50%. When they drank, they reduced the amount they drank by almost 60%. So they picked up the bottle less often, and when they picked it up, they could put it back down. We think this is a really meaningful result for these people." @AdialPharma #Addiction #AlcoholUseDisorder #Alcoholism #AddictionTreatment #MentalHealth adialpharma.com Listen to the podcast here  

Related Post

NEWSLETTER

Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.